Sun Pharma Corporate Overview

Sun Pharma today US Formulations 10th largest generics company in US* with a strong pipeline (94 ANDAs & 9 NDAs awaiting approval) Presence in Specialty branded & generics segments with more than 550 approved products FY21 sales: US$ 1,359 mn (2) India Branded Generics No.1 ranked with 10 classes of doctor categories Leading position in high growth chronic therapies Specializes in technically complex products FY21 sales: US$ 1,393 mn (2) India 33% FY21 International 67% Geographical sales split Market cap: US$ 22 bn (1) Gross Sales: US$ 4,465 mn (2) EBITDA: US$ 1,096 mn (24.5% margin) (2) R&D Investment: 6.5% of Sales Globalized supply chain Strong balance sheet 54% owned by promoter group Revenue Share SUN PHARMA Emerging Markets 18% Western Europe & Other Markets # 15% India FY21 Branded API & Others 6% Generics 31% US Formulation 30% Note: Emerging Markets Presence in about 80 countries across Africa, Americas, Asia and Eastern & Central Europe Key focus markets - Romania, Russia, South Africa, Brazil & Mexico and complementary & affiliated markets FY21 sales: US$ 779 mn (2) (1) As of July, 16, 2021 using spot exchange rate of INR /USD = 74.54 (2) Using average exchange rate for FY21 of INR/USD = 74.23 # Includes Western Europe, Canada, Australia & New Zealand, Japan and other markets. All sales numbers in US$ for 12 months ended March 31, 20201 * Source: IQVIA data for 12 months ended Feb 2021 © Sun Pharmaceutical Industries Limited. All Rights Reserved. Western Europe, Canada, Japan ANZ & others Presence across key markets in Western Europe, Canada, Japan and A&NZ Product portfolio includes specialty products, differentiated offerings for hospitals, injectables & generics for retail market FY21 sales: US$ 649 mn (2) 160

View entire presentation